Texas Biotechnology argatroban
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anticoagulant will be launched in the third quarter, marketing partner SmithKline Beecham says. Argatroban was approved June 30 for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. SmithKline has not yet decided on a brand name for the product, which was approved as Acova. FDA rejected the initial tradename, Novastan, because of its similarity to Immunex's Novantrone